PDF(Pubmed)
Abstract：
Heart failure, a prevailing global health issue, imposes a substantial burden on both healthcare systems and patients worldwide. With an escalating prevalence of heart failure, prolonged survival rates, and an aging demographic, an increasing number of individuals are progressing to more advanced phases of this incapacitating ailment. Against this backdrop, the quest for pharmacological agents capable of addressing the diverse subtypes of heart failure becomes a paramount pursuit. From this viewpoint, the present article focuses on Omecamtiv Mecarbil (OM), an emerging chemical compound said to exert inotropic effects without altering calcium homeostasis. For the first time, as a review, the present article uniquely started from the very basic pathophysiology of heart failure, its classification, and the strategies underpinning drug design, to on-going debates of OM\'s underlying mechanism of action and the latest large-scale clinical trials. Furthermore, we not only saw the advantages of OM, but also exhaustively summarized the concerns in sense of its effects. These of no doubt make the present article the most systemic and informative one among the existing literature. Overall, by offering new mechanistic insights and therapeutic possibilities, OM has carved a significant niche in the treatment of heart failure, making it a compelling subject of study.
摘要：
心力衰竭,一个普遍存在的全球健康问题，给全世界的医疗保健系统和患者带来了沉重负担。随着心力衰竭患病率的上升，延长生存率，和人口老龄化，越来越多的人正在发展到这种丧失行为能力的疾病的更高级阶段。在这种背景下,寻求能够解决不同亚型心力衰竭的药物成为最重要的追求。从这个角度来看,本文的重点是OmecamtivMecarbil(OM)，一种新兴的化合物，据说在不改变钙稳态的情况下发挥正性肌力作用。第一次,作为一个审查,本文从心力衰竭的基本病理生理学出发，其分类,以及支持药物设计的策略，对OM的潜在作用机制和最新的大规模临床试验的持续辩论。此外，我们不仅看到了OM的优势，但也详尽地总结了其影响意义上的担忧。这些无疑使本文成为现有文献中最系统和最翔实的文献。总的来说,通过提供新的机械见解和治疗可能性，OM在心力衰竭的治疗中占据了重要的地位，使它成为一个引人注目的研究主题。
